Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Novel central 5-HT1A receptor agonists characterized in binding and animal studies

Oct. 13, 1998

Celgene initiates pivotal trials with d-MPH

Oct. 9, 1998

Creative BioMolecules receives NIH grant for Parkinson's disease research

Oct. 9, 1998

Elan obtains North American marketing rights for frovatriptan

Oct. 9, 1998

SB receives clearance to market Seroxat for important new indication in the U.K.

Oct. 9, 1998

Novartis submits NDA for Trileptal

Oct. 9, 1998

NeoTherapeutics completes enrollment in phase II trial of Neotrofin

Oct. 9, 1998

Cytogen anticipates selection of new marketing partner for Quadramet

Oct. 8, 1998

Novel antiepileptic agent developed by SK enters clinical trials

Oct. 8, 1998

Lilly to pursue new indication for Zyprexa despite FDA nonapprovable letter

Oct. 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...